Higher rates of b-IFDs ranging between 5.8% and 8.3% were reported in AML patients receiving AFP with isavuconazole, despite fewer drug–drug interactions (DDIs) [50,51,52]. The gene discussed is AFP; the disease is acute myeloid leukemia.